1. In Vivo

Vivoryon Brings 'Diversity' To Therapeutic Approach In Alzheimer’s

 
• By Maire Gerrard

Ulrich Dauer, CEO Vivoryon Therapeutics, the new name for German biotech Probiodrug, talks to In Vivo about introducing more diversity into the Alzheimer’s disease pipeline.

Neuron_Cells

Vivoryon Therapeutics is expected to start enrollment for a Phase IIb trial of its lead Alzheimer’s disease treatment in the second quarter of 2020 in Europe, with topline data due in late-2022. Ulrich Dauer, who joined the company as CEO in 2018, spoke to In Vivo during the recent, virtual BIO-Europe Spring conference about the company’s work in Alzheimer’s, how they are approaching the challenges raised by the coronavirus outbreak and their goals for the remainder of 2020.

Probiodrug changed its name to Vivoryon in June 2019. Dauer said at the time that the new name was “representative...

More from Innovation

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.